Fri Sep 20 12:16:14 UTC 2024: ## Genmab A/S (GMAB) Stock Receives “Buy” Rating from HC Wainwright
**New York, NY – September 20, 2024** – Genmab A/S (NASDAQ:GMAB), a Danish biopharmaceutical company developing antibody therapeutics for cancer and other diseases, received a “buy” rating from investment analysts at HC Wainwright, with a price target of $50.00. This represents a potential upside of 88.82% from the stock’s previous closing price.
The analysts at HC Wainwright are optimistic about Genmab’s future prospects, particularly based on the company’s strong performance in the development and marketing of its key drugs, including DARZALEX, teprotumumab, and Amivantamab.
While HC Wainwright is bullish on GMAB, other analysts hold varying opinions. Morgan Stanley maintained an “equal weight” rating with a $31.00 price target, while Truist Financial lowered their price target from $53.00 to $50.00, but maintained a “buy” rating. JPMorgan Chase & Co. reiterated a “neutral” rating, and BTIG Research lifted their price target to $47.00 and kept their “buy” rating. Royal Bank of Canada upgraded the stock to an “outperform” rating.
Overall, analysts have a “Hold” consensus rating for GMAB, with an average price target of $45.20.
Despite missing earnings estimates in the last quarter, Genmab continues to experience revenue growth. Institutional investors and hedge funds hold 7.07% of the company’s stock, demonstrating continued interest in the company’s potential.
Investors interested in learning more about Genmab A/S can sign up for MarketBeat.com’s FREE daily email newsletter to receive news and analysts’ ratings on the company.
First Piper 